Sanjay Keswani, MBBS, FRCP, Executive Vice President and Chief Medical Officer (CMO) of Annexon, Inc. (the Company), has resigned his position effective February 23, 2022 in order to tend to personal obligations in the United Kingdom. The Company is engaged in a search for a new CMO, and Henk-André Kroon, MD, Senior Vice President of Translational Medicine, will assume responsibility for the Company's clinical development programs on an interim basis.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.735 USD | +3.16% | +4.17% | +4.63% |
Apr. 01 | JPMorgan Raises Price Target on Annexon to $13 From $11, Maintains Overweight Rating | MT |
Mar. 27 | Wells Fargo Adjusts Price Target on Annexon to $12 From $11, Maintains Overweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.63% | 413M | |
-4.66% | 87.53B | |
+1.32% | 40.42B | |
-19.13% | 29.48B | |
+57.86% | 25.43B | |
-17.84% | 11.49B | |
-43.00% | 11.3B | |
-9.14% | 11.1B | |
+5.24% | 8.75B | |
-8.42% | 7.99B |
- Stock Market
- Equities
- ANNX Stock
- News Annexon, Inc.
- Annexon, Inc. Announces Resignation of Sanjay Keswani as Executive Vice President and Chief Medical Officer